Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Jasper Therapeutics’ stock has dropped by more than 50% after the company announced it was looking into the impact of a ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

P YC Therapeutics is set to begin Part B in its single ascending dose (SAD) study of the drug candidate, PYC-003, for ...

Discover a study that compares two key hepatitis C treatments, confirming their effectiveness and revealing cost-saving ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...

In yet another fail for the Duchenne muscular dystrophy (DMD) field, Taiho Pharmaceutical Co. Ltd.’s pizuglanstat (TAS-205) did not meet the primary endpoint in a phase III trial. The phase III ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...